JP2020510704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510704A5 JP2020510704A5 JP2019571809A JP2019571809A JP2020510704A5 JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5 JP 2019571809 A JP2019571809 A JP 2019571809A JP 2019571809 A JP2019571809 A JP 2019571809A JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer
- composition
- composition according
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 40
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 21
- 210000002865 immune cell Anatomy 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 201000005787 hematologic cancer Diseases 0.000 claims description 9
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 9
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 108020001756 ligand binding domains Proteins 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 241001446316 Bohle iridovirus Species 0.000 claims description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076631A JP2023103318A (ja) | 2017-03-15 | 2023-05-08 | 方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704084.1A GB201704084D0 (en) | 2017-03-15 | 2017-03-15 | Method |
| GB1704084.1 | 2017-03-15 | ||
| GB1721603.7 | 2017-12-21 | ||
| GBGB1721603.7A GB201721603D0 (en) | 2017-12-21 | 2017-12-21 | Method |
| PCT/GB2018/050652 WO2018167486A1 (en) | 2017-03-15 | 2018-03-14 | Method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076631A Division JP2023103318A (ja) | 2017-03-15 | 2023-05-08 | 方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510704A JP2020510704A (ja) | 2020-04-09 |
| JP2020510704A5 true JP2020510704A5 (enExample) | 2021-04-22 |
| JP7277388B2 JP7277388B2 (ja) | 2023-05-18 |
Family
ID=61868533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571809A Active JP7277388B2 (ja) | 2017-03-15 | 2018-03-14 | 方法 |
| JP2023076631A Withdrawn JP2023103318A (ja) | 2017-03-15 | 2023-05-08 | 方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076631A Withdrawn JP2023103318A (ja) | 2017-03-15 | 2023-05-08 | 方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11427645B2 (enExample) |
| EP (1) | EP3595705A1 (enExample) |
| JP (2) | JP7277388B2 (enExample) |
| KR (2) | KR20230166145A (enExample) |
| CN (1) | CN110678197A (enExample) |
| AU (2) | AU2018235130B2 (enExample) |
| CA (1) | CA3056542A1 (enExample) |
| WO (1) | WO2018167486A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11126040B2 (en) | 2012-09-30 | 2021-09-21 | Optica Amuka (A.A.) Ltd. | Electrically-tunable lenses and lens systems |
| KR20240165484A (ko) | 2017-04-11 | 2024-11-22 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
| SG11202008399QA (en) | 2018-03-12 | 2020-09-29 | Genmab As | Antibodies |
| EP3773913A1 (en) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| US12195533B2 (en) | 2018-07-24 | 2025-01-14 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same |
| IL296050B2 (en) * | 2018-08-01 | 2024-12-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| TWI863932B (zh) * | 2018-10-11 | 2024-12-01 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| GB201911958D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of t cell production |
| WO2021046500A1 (en) * | 2019-09-05 | 2021-03-11 | Bluebird Bio, Inc. | Transduction efficiency assay |
| US20240092935A1 (en) * | 2019-10-11 | 2024-03-21 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| WO2022074464A2 (en) * | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| EP4337227A2 (en) | 2021-05-14 | 2024-03-20 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| JP2025532982A (ja) * | 2022-09-28 | 2025-10-03 | スパークス バイオサイエンス リミテッド | 白血球免疫グロブリン様受容体サブファミリーｂメンバー２（ｌｉｌｒｂ２）に結合する抗体とその使用 |
| CN117069849B (zh) * | 2023-03-21 | 2024-02-23 | 武汉奥科博泰生物科技有限公司 | 识别nag的单克隆抗体及其应用 |
| CN117074674B (zh) * | 2023-03-23 | 2024-01-23 | 武汉勖瑞生物科技有限责任公司 | 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法 |
| CN119074896A (zh) * | 2024-10-11 | 2024-12-06 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | Il-12在制备治疗t-all的药物中的用途 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5869053A (en) | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| WO1989007947A1 (en) | 1988-03-04 | 1989-09-08 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5118672A (en) | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| BR9106826A (pt) | 1990-08-13 | 1994-01-25 | Isis Pharmaceuticals Inc | Oligonucleotideo ou analogo de oligonucleotideo,processo para modular a producao de uma proteina por um organismo,para tratar um organismo e processos para sintetizar:9(2'-desoxi-2'-substituido-beta-d-ribofuranosil)-guanina e g('-desoxi-2'-fluor-beta-d-ribofuranosil)-guanina |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| CZ137399A3 (cs) | 1996-10-17 | 1999-07-14 | Oxford Biomedica (Uk) Limited | Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| PT1012259E (pt) | 1997-06-04 | 2009-11-06 | Oxford Biomedica Ltd | Vector dirigido a tumor |
| WO2000029428A2 (en) | 1998-11-18 | 2000-05-25 | Oxford Biomedica (Uk) Limited | 5t4 tumour-associated antigen for use in tumour immunotherapy |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP4578678B2 (ja) | 1997-12-22 | 2010-11-10 | オックスフォード バイオメディカ（ユーケー）リミテッド | ウマ伝染性貧血ウイルス（ｅｉａｖ）系 |
| GB2370573A (en) | 1998-11-18 | 2002-07-03 | Oxford Biomedica Ltd | Poxviral vectors |
| GB9825303D0 (en) * | 1998-11-18 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| GB2378704B (en) | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | Uses of 5t4 antigen |
| GB9922361D0 (en) | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| AU1290001A (en) * | 1999-11-18 | 2001-05-30 | Oxford Biomedica (Uk) Limited | Antibodies |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP1347994A2 (en) | 2000-11-13 | 2003-10-01 | Oxford Biomedica (UK) Limited | Canine and feline tumour-associated antigen 5t4 |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| GB0126378D0 (en) | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
| ES2411981T3 (es) | 2002-02-01 | 2013-07-09 | Oxford Biomedica (Uk) Limited | Vector lentivírico |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| GB0215287D0 (en) * | 2002-07-02 | 2002-08-14 | Oxford Biomedica Ltd | 5T4 antigen expression |
| US7662625B2 (en) * | 2002-07-02 | 2010-02-16 | Cancer Research Technology Limited | Methods for detecting the differentiation status of cells using 5T4 antigen expression |
| NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
| RU2007108716A (ru) | 2004-09-10 | 2008-10-20 | Вайет (Us) | Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином |
| JP4926168B2 (ja) | 2005-05-13 | 2012-05-09 | オックスフォード バイオメディカ（ユーケー）リミテッド | ペプチド |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| PT1994055E (pt) * | 2006-03-10 | 2014-09-15 | Wyeth Llc | Anticorpos anti-5t4 e utilizações dos mesmos |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| WO2009070003A2 (en) | 2007-11-30 | 2009-06-04 | Mimos Berhad | An analog read out interface circuit for ion sensor |
| EP2520643B8 (en) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| EP2313784B1 (en) | 2008-07-15 | 2015-02-18 | Oxford BioMedica (UK) Limited | Immunotherapeutic method |
| ES2565439T3 (es) | 2009-01-09 | 2016-04-04 | Oxford Biomedica (Uk) Ltd | Factores |
| WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| ES2405605T3 (es) * | 2009-03-27 | 2013-05-31 | Wyeth Llc | Células iniciadoras de tumores y procedimientos de uso de las mismas |
| GB0918383D0 (en) | 2009-10-20 | 2009-12-02 | Cancer Rec Tech Ltd | Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation |
| JP6133209B2 (ja) | 2010-09-21 | 2017-05-24 | アメリカ合衆国 | 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法 |
| GB201018480D0 (en) | 2010-11-02 | 2010-12-15 | Oxford Biomedica Ltd | Factors |
| ES2596194T3 (es) | 2011-04-01 | 2017-01-05 | Wyeth Llc | Conjugados de anticuerpo-fármaco |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| HUE064187T2 (hu) | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| ES2754397T3 (es) * | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| JP6810685B2 (ja) * | 2014-09-04 | 2021-01-06 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のための栄養膜糖タンパク質（５ｔ４、ｔｐｂｇ）特異的キメラ抗原受容体 |
| AU2016271147B2 (en) | 2015-05-29 | 2022-09-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| WO2019016402A1 (en) * | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
-
2018
- 2018-03-14 KR KR1020237040460A patent/KR20230166145A/ko not_active Withdrawn
- 2018-03-14 KR KR1020197026693A patent/KR102609624B1/ko active Active
- 2018-03-14 AU AU2018235130A patent/AU2018235130B2/en not_active Expired - Fee Related
- 2018-03-14 CN CN201880018043.9A patent/CN110678197A/zh active Pending
- 2018-03-14 CA CA3056542A patent/CA3056542A1/en active Pending
- 2018-03-14 EP EP18715065.1A patent/EP3595705A1/en not_active Withdrawn
- 2018-03-14 JP JP2019571809A patent/JP7277388B2/ja active Active
- 2018-03-14 US US16/490,972 patent/US11427645B2/en active Active
- 2018-03-14 WO PCT/GB2018/050652 patent/WO2018167486A1/en not_active Ceased
-
2022
- 2022-07-27 US US17/815,531 patent/US20230084645A1/en not_active Abandoned
-
2023
- 2023-05-08 JP JP2023076631A patent/JP2023103318A/ja not_active Withdrawn
- 2023-11-29 AU AU2023274115A patent/AU2023274115A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510704A5 (enExample) | ||
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Zhang et al. | Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma | |
| Kirtane et al. | Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead | |
| Frank et al. | Combining T-cell–specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors | |
| Vairy et al. | CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia | |
| Fan et al. | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia | |
| Van de Donk et al. | CD38 antibodies in multiple myeloma: back to the future | |
| Feugier | A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| RU2688692C2 (ru) | Фармацевтическая композиция, обладающая противоопухолевым эффектом, и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| Yurkiewicz et al. | Inotuzumab ozogamicin: A CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia | |
| Bechman et al. | Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy–what are we doing; where are we going? | |
| Ochi et al. | Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy | |
| Pocock et al. | Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia | |
| Zagouri et al. | Emerging antibodies for the treatment of multiple myeloma | |
| Dinner et al. | Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia | |
| Watkins et al. | CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas | |
| EP3819312A1 (en) | Dosing regimen for anti-dll3 agents | |
| Zamagni et al. | Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy | |
| Schultz et al. | New developments in immunotherapy for pediatric solid tumors | |
| CN116554357A (zh) | 一种双特异性嵌合抗原受体（car）及其在制备抗肿瘤药物中的应用 | |
| Savani et al. | New targets for CAR T therapy in hematologic malignancies | |
| Diorio et al. | Harnessing immunotherapy for pediatric T-cell malignancies | |
| Kassner et al. | Current landscape of CD3 bispecific antibodies in hematologic malignancies |